J&J's COVID-19 vaccine shows promise against Delta variant

Johnson & Johnson said late Thursday that its single-shot COVID-19 vaccine showed strong promise against the Delta variant and other emerging strains and also provided durable protection against the infection more broadly.

Data showed that the durability of immune response for recipients of its vaccine lasted at least eight months, the healthcare company said, adding that its vaccine was 85% effective and could also help prevent hospitalization and death. First identified in India, Delta is becoming the globally dominant variant of the coronavirus, according to the World Health Organization.